2. Search Result
Search Result
Results for "

Agonist activity

" in MedChemExpress (MCE) Product Catalog:

1369

Inhibitors & Agonists

1

Screening Libraries

6

Fluorescent Dyes

11

Biochemical Assay Reagents

127

Peptides

18

Inhibitory Antibodies

128

Natural
Products

97

Isotope-Labeled Compounds

7

Click Chemistry

24

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0121B
    Sumatriptan
    5+ Cited Publications

    GR 43175 free base

    		 5-HT Receptor Neurological Disease
    Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research .
    Sumatriptan
  • HY-19711
    STING agonist-1
    4 Publications Verification

    G10

    		 STING Virus Protease Infection
    STING agonist-1 (G10) is human-specific STING agonist that elicits antiviral activity against emerging Alphaviruses. G10 potently blocks replication of Alphavirus species Venezuelan Equine Encephalitis Virus (VEEV) with IC90 of 24.57 μM .
    STING agonist-1
  • HY-143320
    STING agonist-17

    		STING Cancer
    STING agonist-17 (compound 4a) is a potent STING agonist with an IC50 value of 0.062 nM. STING agonist-17 has anti-cancer activity for tumor immunization .
    STING agonist-17
  • HY-B0121
    Sumatriptan succinate
    5+ Cited Publications

    GR 43175 succinate

    		 5-HT Receptor Neurological Disease
    Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan succinate can be used for migraine headache research .
    Sumatriptan succinate
  • HY-164919
    Calotatug ginistinag

    XMT-2056

    		 Antibody-Drug Conjugates (ADCs) EGFR STING Inflammation/Immunology Cancer
    Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate targeting HER2, with an effective payload connected via a linker (LP, HY-148067) to a STING agonist (STING agonist-20, HY-148068), and has potential immune activation and anticancer activity .
    Calotatug ginistinag
  • HY-111358
    TLR7 agonist 1

    		Toll-like Receptor (TLR) Inflammation/Immunology
    TLR7 agonist 1 is a selective TLR7 agonist with an LEC value of 90 nM. TLR7 agonist 1 activates downstream immune regulation and shows no activity against TLR8. TLR7 agonist 1 induces endogenous IFN-α production in mice .
    TLR7 agonist 1
  • HY-107480
    YK11
    1 Publications Verification

    		 Androgen Receptor Metabolic Disease
    YK11 is a partial agonist of androgen receptor, with osteogenic activity.
    YK11
  • HY-10013
    Taranabant
    2 Publications Verification

    MK-0364

    		 Cannabinoid Receptor Metabolic Disease
    Taranabant is a highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist that inhibits the binding and functional activity of various agonists, with a binding Ki of 0.13 nM for the human CB1R in vitro.
    Taranabant
  • HY-139017
    TLR7/8 agonist 4

    		Toll-like Receptor (TLR) Neurological Disease Inflammation/Immunology Cancer
    TLR7/8 agonist 4 (compound 41) is a potent TLR7/8 agonist. TLR7/8 agonist 4 has anti-cancer activity .
    TLR7/8 agonist 4
  • HY-122153
    VSN-16

    		Cannabinoid Receptor Cardiovascular Disease Inflammation/Immunology
    VSN-16 is a cannabinoid receptor agonist with vasodilatory activity. VSN-16 can be used for the study of multiple sclerosis .
    VSN-16
  • HY-P11273
    Urcosimod

    OK 101

    		 Chemerin Receptor Neurological Disease Inflammation/Immunology
    Urcosimod (OK 101) is a lipid-coupled chemokine peptide, a ChemR23 G protein-coupled receptor agonist, which has been shown to have anti-inflammatory and analgesic activities. Urcosimod can be used for dry eye research .
    Urcosimod
  • HY-164860
    Glucocorticoid receptor agonist-5

    		Glucocorticoid Receptor ADC Payload Inflammation/Immunology
    Glucocorticoid receptor agonist-5 (compound 4), a glucocorticoid molecule, is a potent glucocorticoid receptor agonist. Glucocorticoid receptor agonist-5 shows anti-inflammatory and immunosuppressive activity. Glucocorticoid receptor agonist-5 is used as an ADC Cytotoxin for antibody-drug conjugate .
    Glucocorticoid receptor agonist-5
  • HY-147395
    GPR52 agonist-1

    		GPR52 Neurological Disease
    GPR52 agonist-1 is a potent, orally active and blood-brain barrier (BBB) penetrant GPR52 agonist with an pEC50 value of 7.53. GPR52 agonist-1 affects cAMP accumulation through direct interaction with GPR52. GPR52 agonist-1 can significantly suppress Methamphetamine-induced hyperactivity in mice. Antipsychotic activity .
    GPR52 agonist-1
  • HY-152959
    STING agonist-26

    		STING Infection Cancer
    STING agonist-26 (CF508) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .
    STING agonist-26
  • HY-145848
    ERRγ agonist-1

    		Estrogen Receptor/ERR Neurological Disease
    ERRγ agonist-1 is a potent ERRγ agonist. ERRγ agonist-1 increases transcriptional activities of ERRγ. ERRγ agonist-1 has the potential for the research of neuropsychological disorders .
    ERRγ agonist-1
  • HY-145961
    TLR7 agonist 4

    		Toll-like Receptor (TLR) TNF Receptor Cancer
    TLR7 agonist 4 is a TLR7 agonist with pro-inflammatory cytokine-stimulating activity. TLR7 agonist 4 modulates TLR7 activity to stimulate the production of pro-inflammatory cytokines. TLR7 agonist 4 stimulates mouse bone marrow-derived macrophages to produce the pro-inflammatory cytokine TNFα. TLR7 agonist 4 can be conjugated with antibodies to form conjugates. TLR7 agonist 4 is applicable to cancer research .
    TLR7 agonist 4
  • HY-152956
    STING agonist-23

    		STING Infection Cancer
    STING agonist-23 (CF502) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .
    STING agonist-23
  • HY-114411
    ERRγ inverse agonist 1

    		Estrogen Receptor/ERR Cancer
    ERRγ inverse agonist 1 (Compound 12) is a selective ERRγ inverse agonist with an IC50 value of 0.040 μM against ERRγ. ERRγ inverse agonist 1 inhibits the activity of ERRγ at the functional level. ERRγ inverse agonist 1 can be used in the research of anaplastic thyroid cancer .
    ERRγ inverse agonist 1
  • HY-173556
    GPR84 agonist-2

    		GPR84 Inflammation/Immunology
    GPR84 agonist-2 is a selective GPR84 agonist with no activity at free fatty acid receptors. GPR84 agonist-2 enhances GPR84-mediated signaling above basal levels and potentiates agonist-induced GPR84 activation. GPR84 agonist‑2 can be used for research on GPR84-related physiological mechanisms .
    GPR84 agonist-2
  • HY-W193844
    MLS001006105

    ZINC13684400

    		 GPR65 Inflammation/Immunology
    MLS001006105 (ZINC13684400) is a GPR65 allosteric agonist. MLS001006105 displays GPR65 allosteric agonist activity at pH 8.40 but not at lower pH .
    MLS001006105
  • HY-12835
    S1P1 agonist III

    		LPL Receptor Inflammation/Immunology
    S1P1 agonist III is an orally active hS1P1 agonist with an EC50 value of 18 nM. S1P1 agonist III shows limited activity against hS1P3. S1P1 agonist III can be used in the research of multiple sclerosis .
    S1P1 agonist III
  • HY-N12093
    Cevadine

    		Sodium Channel Parasite Infection
    Cevadine is a voltage-sensitive sodium channel agonist. Cevadine has insecticidal activity .
    Cevadine
  • HY-104069
    S1P1 agonist 1

    		LPL Receptor Inflammation/Immunology
    S1P1 Agonist 1 is a S1P1 agonist with immunomodulatory activities.
    S1P1 agonist 1
  • HY-152961
    STING agonist-28

    		STING Infection
    STING agonist-28 (CF510) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .
    STING agonist-28
  • HY-176837
    NOD2/TLR4 agonist-1

    		Toll-like Receptor (TLR) NOD-like Receptor (NLR) Inflammation/Immunology
    NOD2/TLR4 agonist-1 (Compound 2) is a NOD2/TLR4 dual agonist. NOD2/TLR4 agonist-1 lacks immunostimulatory activity and serves as an important negative control in research .
    NOD2/TLR4 agonist-1
  • HY-156532
    5-HT2C agonist-3

    		5-HT Receptor Neurological Disease
    5-HT2C agonist-3 ((+)-19) is a selective 5-HT2C agonist (EC50: 24 nM, Ki: 78 nM). 5-HT2C agonist-3 has antipsychotic drug-like activity. 5-HT2C agonist-3 blocks Amphetamine-induced hyperactivity .
    5-HT2C agonist-3
  • HY-170992
    Autophagy agonist-1

    		Autophagy CDK Atg8/LC3 PINK1/Parkin Cancer
    Autophagy agonist-1 (compound 22) is an Autophagy agonist. Autophagy agonist-1 exhibits significant anticancer activity against HepG2 cells and normal cells with IC50s of 8.8 μM and > 50 μM. Autophagy agonist-1 induces G1/S phase cell cycle arrest and inhibits CDK4 and CyclinD1 expression while upregulating P21. Autophagy agonist-1 promotes the accumulation of autophagosomes and the proteins LC3 and PINK1, enhancing autophagy and mitophagy in HepG2 cells .
    Autophagy agonist-1
  • HY-175288
    αMβ2 integrin agonist-1

    		Integrin JNK ERK Inflammation/Immunology Cancer
    αMβ2 integrin agonist-1 (Compound 8) is a highly selective αMβ2 integrin agonist with anti-inflammatory activity (EC50=1.4 nM). αMβ2 integrin agonist-1 activates integrin-mediated cell adhesion and JNK/ERK signaling. αMβ2 integrin agonist-1 induces tumor-associated macrophage repolarization and enhances antitumor T-cell immune responses. αMβ2 integrin agonist-1 is promising for research of cancers and chronic inflammatory diseases (e.g., pancreatic cancer, rheumatoid arthritis) .
    αMβ2 integrin agonist-1
  • HY-117196
    GW 9578
    1 Publications Verification

    		 PPAR Metabolic Disease Inflammation/Immunology
    GW9578 is a subtype-selective PPARα agonist (EC50s of 5 and 50 nM for murine and human PPAR-α) with potent lipid-lowering activity .
    GW 9578
  • HY-179063
    5-HT2A receptor agonist-13

    		5-HT Receptor Dopamine Receptor Serotonin Transporter Neurological Disease
    5-HT2A receptor agonist-13 (Compound 28c) is a partial agonist of the 5-HT2A receptor, with an EC50 value of 416.9 nM and a Ki value of 113.9 nM. 5-HT2A receptor agonist-13 exhibits very weak agonistic activity towards the 5-HT2B receptor (EC50 = 120.2 nM), D2 receptor (Ki = 1298 nM), and has no activity towards the 5-HT2C receptor. 5-HT2A receptor agonist-13 exhibits weak inhibitory activity on the serotonin transporter (SERT) (EC50 = 977.2 nM). 5-HT2A receptor agonist-13 has antidepressant activity in mouse models and does not induce hallucinogenic behavior. 5-HT2A receptor agonist-13 can be used for the study of major depressive disorder (MDD) and treatment-resistant depression (TRD) .
    5-HT2A receptor agonist-13
  • HY-137525
    NTRC-808

    		Neurotensin Receptor Neurological Disease
    NTRC-808 is a nonpeptide selective GPCR neurotensin receptor type 2 (NTS2) partial agonist with an EC50 of 14 nM and Ki of 88 nM. NTRC-808 has higher selectivity for NTS2 than for NTS1. NTRC-808 has antipsychotic and analgesic activity .
    NTRC-808
  • HY-152960
    STING agonist-27

    		STING Infection
    STING agonist-27 (CF509) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, exhibits activity against SARS-CoV series strains .
    STING agonist-27
  • HY-152962
    STING agonist-29

    		STING Infection
    STING agonist-29 (CF511) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, exhibits activity against SARS-CoV series strains .
    STING agonist-29
  • HY-147834
    STING agonist-9

    		STING Cancer
    STING agonist-9 (Compound 45) is a potent STING agonist with an EC50 of 1.2 nM and 32.82 μM against h-STING and m-STING, respectively. STING agonist-9 shows antitumor activity .
    STING agonist-9
  • HY-146141
    EphA2 agonist 2

    		Ephrin Receptor Cancer
    EphA2 agonist 2 (Lead compound) is a selective EphA2 agonist with antitumor activities. EphA2 agonist 2 can cross the BBB .
    EphA2 agonist 2
  • HY-121677
    Norgestomet

    		Progesterone Receptor Others
    Norgestomet is a compound with progesterone receptor agonist activity. The synthetic product has high purity and agonist activity on the progesterone receptor, while its 17β-isomer is inactive.
    Norgestomet
  • HY-146275
    LXRβ agonist-3

    		LXR Cancer
    LXRβ agonist-3 (compound 4-13) is a potent and selective LXRβ (liver X receptor β) agonist, with an EC50 of 0.095 μM. LXRβ agonist-3 efficiently inhibits U87EGFRvIII cell, with an IC50 of 3.75 μM. LXRβ agonist-3 shows antitumor activity, and can inhibit glioblastoma .
    LXRβ agonist-3
  • HY-B0121R
    Sumatriptan succinate (Standard)

    GR 43175 succinate (Standard)

    		 5-HT Receptor Reference Standards Neurological Disease
    Sumatriptan (succinate) (Standard) is the analytical standard of Sumatriptan (succinate). This product is intended for research and analytical applications. Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research .
    Sumatriptan succinate (Standard)
  • HY-B0121BR
    Sumatriptan (Standard)

    GR 43175 free base (Standard)

    		 5-HT Receptor Reference Standards Neurological Disease
    Sumatriptan (Standard) is the analytical standard of Sumatriptan. This product is intended for research and analytical applications. Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research .
    Sumatriptan (Standard)
  • HY-172671
    STING agonist-43

    		STING Cancer
    STING agonist-43 (Compound 67) is a selective STING agonist (EC50: 20.53 μM). STING agonist-43 selectively amplifies cGAMP-dependent STING pathway activation by modulating STING oligomerization. B16.F10 has antitumor activity in a mouse melanoma model. STING agonist-43 can be used for the study of cancer immunity .
    STING agonist-43
  • HY-152957
    STING agonist-24

    		STING Infection
    STING agonist-24 (CF504) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .
    STING agonist-24
  • HY-152958
    STING agonist-25

    		STING Infection
    STING agonist-25 (CF505) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .
    STING agonist-25
  • HY-178966
    STING agonist-48

    		STING Infection Inflammation/Immunology
    STING agonist-48 is a potent STING agonist that exhibits STING-dependent activity in vitro (EC50 = 4.02 μM). STING agonist-48 prefers to bind with the transmembrane domain (TMD) over the cytosolic cyclic dinucleotide (CDN) domain. STING agonist-48 shows adjuvant efficacy, enhancing IgG and Th1/Th2 cytokine responses in humanized STING mice. STING agonist-48 can be used for the study of inflammation-related diseases .
    STING agonist-48
  • HY-177493A
    SSTR3 agonist-1 TFA

    		Somatostatin Receptor Metabolic Disease Endocrinology
    SSTR3 agonist-1 TFA is a potent, orally active, and selective SSTR3 agnoist (EC50 =0.14 nM). SSTR3 agonist-1 TFA binds to SSTR3 receptor to inhibit cAMP activity. SSTR3 agonist-1 TFA decreases kidney weight and kidney cystic index (KCI) in a mouse model of autosomal dominant polycystic kidney disease (ADPKD). SSTR3 agonist-1 TFA can be used for ADPKD research .
    SSTR3 agonist-1 TFA
  • HY-173079
    TLR7 agonist 30

    		Toll-like Receptor (TLR) Drug-Linker Conjugates for ADC Cancer
    TLR7 agonist 30 (compound 2) is an agent-linker conjugate for ADC. TLR7 agonist 30 contains a TLR7 agonist (compound 1) and a cleavable linker, and has potent anti-tumor activity .
    TLR7 agonist 30
  • HY-172814A
    OT-R agonist 1 TFA

    		Oxytocin Receptor Vasopressin Receptor Neurological Disease
    OT-R agonist 1 TFA (compound 5) is an oxytocin receptor agonist with an EC50 of 0.39 nM. OT-R agonist 1 TFA shows V1A antagonist activity with an EC50 of 2432 nM and can be used for study of CNS disorders .
    OT-R agonist 1 TFA
  • HY-168159
    TLR7 agonist 27

    		Toll-like Receptor (TLR) NOD-like Receptor (NLR) Inflammation/Immunology
    TLR7 agonist 27 (compound 24) is a potent TLR7 agonist with an EC50 of 238.1 nM. TLR7 agonist 27 shows weak agonistic activity against NOD2 (nucleotide-binding oligomerization domain 2) (EC50 of 6.2 μM). TLR7 agonist 27 is a potent immunostimulant, and can be used as a vaccine adjuvant and/or immunotherapeutic .
    TLR7 agonist 27
  • HY-168051
    TLX agonist 2

    		Orphan Nuclear Receptor Neurological Disease Cancer
    TLX agonist 2 (compound 31) is a TLX agonist (EC50=0.1 μM; Kd=0.16 μM). TLX agonist 2 promotes TLX transcriptional activity and enhances the expression of TLX target genes by binding to TLX. TLX agonist 2 can be used in the study of neurodegenerative diseases .
    TLX agonist 2
  • HY-19394
    CLX-0921

    		PPAR Metabolic Disease
    CLX-0921 is an orally active PPARγ agonist with an IC50 of 1.54 μM. CLX-0921 has a potent antihyperglycemic activity, and can be used for the study of type 2 diabetes .
    CLX-0921
  • HY-19394A
    (E)-CLX-0921

    		PPAR Metabolic Disease
    (E)-CLX-0921 is the E-isomer of CLX-0921 (HY-19394). CLX-0921 is an orally active PPARγ agonist with an IC50 of 1.54 μM. CLX-0921 has a potent antihyperglycemic activity, and can be used for the study of type 2 diabetes .
    (E)-CLX-0921

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: